Page 311 - Read Online

Page 4 of 4 Liu et al. Hepatoma Res 2019;5:30 I http://dx.doi.org/10.20517/2394-5079.2019.27

J Hepatol 2017;302-9.
4. Liu W, Wu J, Du Y, Cao G. Cancer Evolution-Development: experience of hepatitis B virus-induced hepatocarcinogenesis. Curr Oncol
2016;23:e49-56.
5. Deng Y, Du Y, Zhang Q, Han X, Cao G. Human cytidine deaminases facilitate hepatitis B virus evolution and link inflammation and
hepatocellular carcinoma. Cancer Lett 2014;343:161-71.
6. Cao G. Cancer Evo-Dev, a novel hypothesis derived from studies on hepatitis B virus-induced carcinogenesis. Hepatoma Res
2017;3:241-59.
7. Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, et al. An APOBEC cytidine deaminase mutagenesis pattern is
widespread in human cancers. Nat Genet 2013;45:970-6.
8. Wang D, Li X, Li J, Lu Y, Zhao S, et al. APOBEC3B interaction with PRC2 modulates microenvironment to promote HCC
progression. Gut 2019. Epub ahead of print. doi: 10.1136/gutjnl-2018-317601.
9. Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus
cccDNA. Science 2014;343:1221-8.
10. Liu W, Wu J, Yang F, Ma L, Ni C, et al. Genetic polymorphisms predisposing the interleukin-6-induced APOBEC3B-UNG imbalance
increase HCC risk via promoting the generation of APOBEC-signature HBV mutations. Clin Cancer Res 2019. Epub ahead of print.
doi: 10.1158/1078-0432.CCR-18-3083
11. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, et al. Signatures of mutational processes in human cancer. Nature
2013;500:415-21.